Given the high proportion of IDH-mutated diffuse astrocytoma, CNS WHO grade 4, in secondary GBM, it would be advantageous to potentially extend the IDH inhibitor trial cohort to GBM patients so as to evaluate the therapeutic value of IDH inhibitors in secondary GBM. This evidence concerns the gene IDH1 and glioblastoma.